1)日本癌治療学会,日本胃癌学会,GIST研究会(編):GIST診療ガイドライン第2版補訂版.金原出版,2010
2)Blanke CD, Demetri GD, von Mehren M, et al:Long-term results from randomized phaseII trial of standard-versus higher dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol 26:620-625, 2008
3)Desai J, Shankar S, Heinrich M, et al:Clonal evolution of resistance to imatinib in patients with metastatic gastrointestinal stromal tumors. Clin Cancer Res 13:5398-5405, 2007
4)Rutkowski P, Nowecki Z, Nyckowski P, et al:Surgical treatment of patients with initially inoperable and/or metastatic gastrointestinal stromal tumors(GIST)during therapy with imatinib mesylate. J Surg Oncol 93:304-311, 2006
5)Raut CP, Posner M, Desai J, et al:Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors. J Clin Oncol 24:2325-2331, 2006
6)Gronchi A, Fiore M, Miselli F, et al:Surgery of residual disease following molecular-targeted therapy with imatinib mesylate in advanced/metastatic GIST. Ann Surg 245:341-346, 2007
7)DeMatteo RP, Maki RG, Singer S, et al:Results of tyrosine kinase inhibitor therapy followed by surgical resection for metastatic gastrointestinal stromal tumor. Ann Surg 245:347-352, 2007
8)Sym SJ, Ryu MH, Lee JL, et al:Surgical intervention following imatinib treatment in patients with advanced gastrointestinal stromal tumors(GISTs). J Surg Oncol 98:27-33, 2008
9)Bauer S, Hartmann JT, de Wit M, et al:Resection of residual disease in patients with metastatic gastrointestinal stromal tumors responding to treatment with imatinib. Int J Cancer 117:16-25, 2005